NEW YORK – Dutch oncology company Merus has partnered with Sema4 to identify patients with solid tumors who harbor NRG1 fusions and are eligible to enroll in the ongoing Phase I/II eNRGy trial evaluating its bispecific antibody zenocutuzumab.
NEW YORK – Dutch oncology company Merus has partnered with Sema4 to identify patients with solid tumors who harbor NRG1 fusions and are eligible to enroll in the ongoing Phase I/II eNRGy trial evaluating its bispecific antibody zenocutuzumab.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.